Cytomegalovirus (CMV) infection is the most important cause of mental retardation and sensorineural hearing loss. Antiviral treatment with valganciclovir, a relatively new but potential toxic oral drug, is recommended to prevent further hearing deterioration. In this retrospective cohort study we evaluated the relation between the dose of valganciclovir and the reduction of CMV viral load, as well as the toxicity. All neonates with gestational age <32 weeks with CMV infection treated with oral valganciclovir (30 mg/kg/day) were included. Time interval to reach CMV viral load below detection level (<250 copies/ml) was determined. Toxicity was measured by plasma trough levels, thrombocytopenia and leukopenia. Data of 6 infants, median gestational age 252 weeks, were analyzed. Time interval between start of therapy and viral load below detection level was 25 - 54 days. In total, 37 through plasma samples were analyzed. Of these, 28 were in the normal range, 3 above and 6 under the target concentration. Mild transient leukopenia occurred in 1 infant. No thrombocytopenia occurred. Conclusion: Antiviral treatment of CMV infection with oral valganciclovir results in adequate plasma through levels. Also, a progressive reduction of viral load in the urine below detection level was reached within 25 - 54 days, without serious short time side effects.
References
[1]
Goderis, J., De Leenheer, E., Smets, K., van Hoecke, H., Keymeulen, A. and Dhooge, I. (2014) Hearing Loss and Congenital CMV Infection: A Systematic Review. Pediatrics, 134, 972-982. https://doi.org/10.1542/peds.2014-1173
[2]
Fowler, K.B. and Boppana, S.B. (2006) Congenital Cytomegalovirus (CMV) Infection and Hearing Deficit. Journal of Clinical Virology, 35, 226-231.
https://doi.org/10.1016/j.jcv.2005.09.016
[3]
Rosenthal, L.S., Fowler, K.B., Boppana, S.B., Britt, W.J., Pass, R.F., Schmid, S.D., et al. (2009) Cytomegalovirus Shedding and Delayed Sensorineural Hearing Loss: Results from Longitudinal Follow-Up of Children with Congenital Infection. The Pediatric Infectious Disease Journal, 28, 515-520.
https://doi.org/10.1097/INF.0b013e318198c724
[4]
Lombardi, G., Garofoli, F. and Stronati, M. (2010) Congenital Cytomegalovirus Infection: Treatment, Sequelae and Follow-Up. The Journal of Maternal-Fetal & Neonatal Medicine, 23, 45-48. https://doi.org/10.3109/14767058.2010.506753
[5]
Meine Jansen, C.F., Toet, M.C., Rademaker, C.M.A., Ververs, T.F.F., Gerards, L.J. and van Loon, A.M. (2005) Treatment of Symptomatic Congenital Cytomegalovirus Infection with Valganciclovir. Journal of Perinatal Medicine, 33, 364-366.
https://doi.org/10.1515/JPM.2005.065
[6]
Amir, J., Wolf, D.G. and Levy, I. (2010) Treatment of Symptomatic Congenital Cytomegalovirus Infection with Intravenous Ganciclovir Followed by Long-Term Oral Valganciclovir. European Journal of Pediatrics, 169, 1061-1067.
https://doi.org/10.1007/s00431-010-1176-9
[7]
Kimberlin, D.W., Acosta, E.P., Sánches, P.J., Sood, S., Agrawal, V., Homans, J., et al. (2008) Pharmacokinetic and Pharmacodynamics Assessment of Oral Valganciclovir in the Treatment of Symptomatic Congenital Cytomegalovirus Disease. The Journal of Infectious Diseases, 197, 836-845. https://doi.org/10.1086/528376
[8]
Stronati, M., Lombardi, G., Garofoli, F., Villani, P. and Regazzi, M. (2013) Pharmacokinetics, Pharmacodynamics and Clinical Use of Valganciclovir in Newborns with Symptomatic Congenital Cytomegalovirus Infection. Current Drug Metabolism, 14, 208-215.
[9]
Galli, L., Novelli, A., Chiappini, E., Gervaso, P., Cassetta, M.I., Fallani, S. and de Martino, M. (2007) Valganciclovir for Congenital CMV Infection: A Pilot Study on Plasma Concentration in Newborns and Infants. The Pediatric Infectious Disease Journal, 26, 451-453. https://doi.org/10.1097/01.inf.0000261111.90075.4d
[10]
Lombardi, G., Garofoli, F., Villani, P., Tizzoni, M., Angelini, M., Cusato, M., et al. (2009) Oral Valganciclovir Treatment in Newborns with Symptomatic Congenital Cytomegalovirus Infection. European Journal of Clinical Microbiology & Infectious Diseases, 28, 1465-1470. https://doi.org/10.1007/s10096-009-0806-5
[11]
Boppana, S.B., Fowler, K.B., Pass, R.F., Rivera, L.B., Bradford, R.D., Lakeman, F.D. and Britt, W.J. (2005) Congenital Cytomegalovirus Infection: Association between Virus Burden in Infancy and Hearing Loss. Journal of Pediatrics, 146, 817-823.
[12]
Lanari, M., Lazzarotto, T., Venturi, V., Papa, I., Gabrielli, L., Guerra, B., et al. (2006) Neonatal Cytomegalovirus Blood Load and Risk of Sequelae in Symptomatic and Asymptomatic Congenitally Infected Newborns. Pediatrics, 117, e76-e83.
https://doi.org/10.1542/peds.2005-0629
[13]
Gill, F.M. (1983) Thrombocytopenia in the Newborn. Seminars in Perinatology, 7, 201-212.
[14]
Forner, G., Abate, D., Mengoli, C., Palù, G. and Gussetti, N. (2015) High Cytomegalovirus (CMV) DNAemia Predicts CMV Sequelae in Asymptomatic Congenitally Infected Newborns Born to Women with Primary Infection During Pregnancy. The Journal of Infectious Diseases, 212, 67-71. https://doi.org/10.1093/infdis/jiu627
[15]
Rivera, L.B., Boppana, S.B., Fowler, K.B., Britt, W.J., Stagno, S. and Pass, R.F. (2002) Predictors of Hearing Loss in Children with Symptomatic Congenital Cytomegalovirus Infection. Pediatrics, 110, 762-767. https://doi.org/10.1542/peds.110.4.762
[16]
Rawlinson, W.D., Boppana, S.B., Fowler, K.B., Kimberlin, D.W., Lazzarotto, T., Alain, S., et al. (2017) Congenital Cytomegalovirus Infection in Pregnancy and the Neonate: Consensus Recommendations for Prevention, Diagnosis, and Therapy. The Lancet Infectious Diseases, 17, e177-e188.
[17]
Dollard, S.C., Grosse, S.D. and Ross, D.S. (2007) New Estimates of the Prevalence of Neurological and Sensory Sequelae and Mortality Associated with Congenital Cytomegalovirus Infection. Reviews in Medical Virology, 17, 355-363.
https://doi.org/10.1002/rmv.544
[18]
Lombardi, G., Garofoli, F., Manzoni, P. and Stronati, M. (2012) Breast Milk-Acquired Cytomegalovirus Infection in Very Low Birth Weight Infants. The Journal of Maternal-Fetal & Neonatal Medicine, 25, 57-62.
https://doi.org/10.3109/14767058.2012.712345
[19]
Narvaez-Arzate, R.V., Olguin-Mexquitic, L., Lima-Roge, L.V., Noyola, D.E., Barrios-Compaen, L.M. and Villegas-Alvarez, C. (2013) Cytomegalovirus Infection in Infants Admitted to a Neonatal Intensive Care Unit. The Journal of Maternal-Fetal & Neonatal Medicine, 26, 1103-1106. https://doi.org/10.3109/14767058.2013.770459
[20]
Turner, K.M., Lee, H.C., Boppana, S.B., Carlo, W.A. and Randolph, D.A. (2014) Incidence and Impact of CMV Infection in Very Low Birth Weight Infants. Pediatrics, 133, 609-615. https://doi.org/10.1542/peds.2013-2217
[21]
Kimberlin, D.W., Jester, P.M., Sánchez, P.J., Ahmed, A., Arav-Boger, R., Michaels, M.G., et al. (2015) Valganciclovir for Symptomatic Congenital Cytomegalovirus Disease. The New England Journal of Medicine, 372, 933-943.
https://doi.org/10.1056/NEJMoa1404599
